These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37331810)

  • 1. Characteristics of adverse event reports among people living with human immunodeficiency virus (HIV) in Japan: Data mining of the Japanese Adverse Drug Event Report database.
    Tanaka H; Satoh M; Takigawa M; Onoda T; Ishii T
    Drug Discov Ther; 2023 Jul; 17(3):183-190. PubMed ID: 37331810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Time-To-Onset and Factors Affecting Clinical Outcomes of Immune Reconstitution Inflammatory Syndrome in People Living with HIV Using Data from the Japanese Spontaneous Reporting Database.
    Tanaka H; Wada T; Ohyama KO; Ishii T
    J Pharm Pharm Sci; 2021; 24():153-160. PubMed ID: 33836138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
    Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
    BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan.
    Naito T; Mori H; Fujibayashi K; Fukushima S; Yuda M; Fukui N; Tsukamoto S; Suzuki M; Goto-Hirano K; Kuwatsuru R
    Sci Rep; 2022 Feb; 12(1):1732. PubMed ID: 35110641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.
    Ruzicka DJ; Kamakura M; Kuroishi N; Oshima N; Yamatani M; Yi J; Crawford B; Tsukada K; Oka S
    PLoS One; 2022; 17(6):e0269779. PubMed ID: 35700215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years.
    Şahin EA; Mavi D; Kara E; Sönmezer MÇ; İnkaya AÇ; Ünal S
    Postgrad Med; 2022 Aug; 134(6):635-640. PubMed ID: 35671079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential drug-drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan.
    Kunimoto Y; Matamura R; Ikeda H; Fujii S; Kimyo T; Kitagawa M; Nakata H; Kobune M; Miyamoto A; Fukudo M
    J Pharm Health Care Sci; 2021 Dec; 7(1):43. PubMed ID: 34847955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Influence of the Rapid Increase in the Number of Adverse Event Reports for COVID-19 Vaccine on the Disproportionality Analysis Using JADER.
    Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Shimizu T
    In Vivo; 2023; 37(1):345-356. PubMed ID: 36593055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.
    Parbie PK; Abana CZ; Kushitor D; Asigbee TW; Ntim NAA; Addo-Tetebo G; Ansong MRD; Ofori SB; Mizutani T; Runtuwene LR; Nishizawa M; Ishikawa K; Kiyono H; Ampofo WK; Matano T; Bonney EY; Kikuchi T
    Front Microbiol; 2022; 13():973771. PubMed ID: 36090108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan.
    Naito T; Suzuki M; Fukushima S; Yuda M; Fukui N; Tsukamoto S; Fujibayashi K; Goto-Hirano K; Kuwatsuru R
    HIV Med; 2022 May; 23(5):485-493. PubMed ID: 34821006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality evaluation of the Japanese Adverse Drug Event Report database (JADER).
    Tsuchiya M; Obara T; Sakai T; Nomura K; Takamura C; Mano N
    Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):173-181. PubMed ID: 31823506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis.
    Anzai T; Takahashi K; Watanabe M; Mochizuki M; Murashima A
    BMC Psychiatry; 2020 Mar; 20(1):118. PubMed ID: 32164630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
    Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
    Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse Event Trends Associated with OTC Analgesic and Antipyretic Drug: Data Mining of the Japanese Adverse Drug Event Report Database].
    Hasegawa S; Hatahira H; Naganuma M; Shimauchi A; Sasaoka S; Motooka Y; Fukuda A; Abe J; Nakao S; Kato Y; Ohmori T; Iguchi K; Nakamura M
    Yakugaku Zasshi; 2017; 137(10):1301-1311. PubMed ID: 28966270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypharmacy in elderly patients in Japan: Analysis of Japanese real-world databases.
    Mabuchi T; Hosomi K; Yokoyama S; Takada M
    J Clin Pharm Ther; 2020 Oct; 45(5):991-996. PubMed ID: 31986233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.